[Federal Register Volume 80, Number 214 (Thursday, November 5, 2015)]
[Notices]
[Page 68547]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-28245]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of 
Therapeutics To Treat Brain Injury and Neurodegenerative Disease

AGENCY: National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7, that the National Institute of Diabetes and Digestive and 
Kidney Diseases, National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an exclusive patent 
license to Astrocyte Pharmaceuticals, Inc., (``Astrocyte''), a company 
incorporated under the laws of Delaware and having an office in 
Cambridge, Massachusetts, to practice the following inventions embodied 
in the following patent applications: US Provisional Patent Appl. No. 
60/176,373 entitled, ``Methanocarba cycloalkyl nucleoside analogues,'' 
filed 14 Jan 2000 [HHS reference E-176-1999/0-US-01]; Intl. Appl. No. 
PCT/US01/00981, entitled, ``Methanocarba cycloalkyl nucleoside 
analogues,'' filed 12 Jan 2001 [HHS reference E-176-1999/0-PCT-02]; 
Australia Patent No. 2001230913, issued 13 Oct 2005 [HHS reference E-
176-1999/0-AU-03]; Canada Patent No. 2.397,366, issued 15 Mar 2011 [HHS 
reference E-176-1999/0-CA-04]; European Patent Appl. No. 01903043.6 
entitled, filed 12 Jan 2001 [HHS Ref No E-176-1999/0-EP-05]; US Patent 
No. 7,087,589, issued 8 Aug 2006 [HHS reference E-176-1999/0-US-06]; US 
patent No. 7,790,735, issued 8 Aug 2006 [HHS reference E-176-1999/0-US-
07]; and Great Britain patent No. 1252160, issued 16 Aug 2006 [HHS 
reference E-176-1999/0-US-08]. The patent rights in these inventions 
have been assigned to the United States of America. The territories 
included in this license may be worldwide. The field of use may be 
related to ``Use of the patent rights in the development and sale of 
therapeutics for cerebral trauma, stroke, and neurodegenerative 
disorders.''

DATES: Only written comments or applications for a license (or both) 
which are received by the Technology Advancement Office of the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on or 
before November 20, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, patents, 
inquiries, comments, and other materials relating to the contemplated 
exclusive license should be directed to: Patrick McCue, Ph.D., Senior 
Licensing and Patenting Manager, Technology Advancement Office, The 
National Institute of Diabetes and Digestive and Kidney Diseases, 12A 
South Drive, Bethesda, MD 20892, Telephone: (301) 435-5560; Email: 
[email protected]. A signed confidentiality non-disclosure 
agreement will be required to receive copies of any patent applications 
that have not been published by the United States Patent and Trademark 
Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: 
    The technology provides novel nucleoside and nucleotide derivatives 
that are agonist or antagonists of P1 and P2 receptors and may be 
useful in the treatment or prevention of various diseases including 
airway diseases, cancer, cardiac arrhythmias, cardiac ischemia, 
epilepsy, and Huntington's Disease.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the NIDDK 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.
    Properly filed competing applications for a license received by the 
NIDDK in response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 30, 2015.
Anna Z. Amar,
Acting Deputy Director, Technology Advancement Office, National 
Institute of Diabetes and Digestive and Kidney Diseases, National 
Institutes of Health.
[FR Doc. 2015-28245 Filed 11-4-15; 8:45 am]
BILLING CODE 4140-01-P